OBR News Hub

(BMS) Aug 17, 2018 - Bristol-Myers Squibb Company today announced that Opdivo (nivolumab) received approval from the U.S. Food and Drug Administration (FDA) as the first and only Immuno-Oncology treatment option for patients with metastatic small cell lung cancer (SCLC) whose cancer has progressed after platinum-based chemotherapy and at least one other line of therapy.

Approval for this indication has been granted under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Read Article (You will be redirected to BMS)
Today's Other Featured News Articles
View full issue >>
There are no featured articles to show.
Yesterday's Featured News Articles
News Commentary
Editor Image
13 Jan, 2020 | by Dean Gesme, MD
C-C Chemokine Receptors (CCR5 or CD195) are ubiquitous on immune cells and play...
View Comment
Editor Image
13 Jan, 2020 | by Howard Sandler, MD, MS, FASTRO
Radiotherapy as primary treatment (along with TUR and chemotherapy) is having a...
View Comment